Pfizer Plans Consolidation in Cambridge

CAMBRIDGE, MA-Pharmaceutical giant Pfizer Inc. said Thursday it's consolidating its presence here, relocating most of the R&D staff currently housed in Cambridge North to new development under construction in Kendall Square. Further, a Pfizer spokeswoman tells GlobeSt.com that “to best utilize our real estate in Massachusetts, we will sell or sub-lease buildings 87, 200, and 35 Cambridge Park Dr., and 620 Memorial Dr,” all in Cambridge North.

“Pfizer remains committed to maintaining its presence in Massachusetts, given the state's support for the biopharmaceutical industry,” the spokeswoman says. “At this same time, Pfizer must ensure that we utilize our global real estate most efficiently—including our sites in Massachusetts.”

To that end, the consolidation of R&D into 610 Main St. in Kendall Square is intended “to create a single, integrated Pfizer R&D community in Cambridge that can easily access and collaborate with world-class biomedical researchers and other partners.” She adds that the company anticipates “minimal impact to the size of Pfizer's workforce in the state of Massachusetts, given that most colleagues will be moving to other Pfizer sites or leased space in Massachusetts.”

The majority of R&D staff will relocate to Kendall Square in early 2014, the spokeswoman says. “We are exploring all options to determine appropriate locations for colleagues, including relocation to Pfizer's Andover campus. The target is to begin to vacate our Cambridge Park Drive campus toward the end of 2013,” with the majority of the move taking place early the following year.

Thereafter, Pfizer will launch an RFP to select a brokerage firm “that can help the company obtain the right value to mutually benefit the company and the Cambridge community," says ther spokeswoman.